Chen et al.
219
and concentrated. The crude product was purified by chroma-
tography (silica gel; petroleum ether:ethyl acetate = 3:1) to
afford 3h and was crystallized from a mixture of EtOAc
with hexanes.
8.5 Hz), 7.59 (1H, s), 9.87 (1H, brs). 13C NMR (125 MHz,
CDCl3) d: 14.2, 21.8, 60.3, 118.0, 122.4, 126.3, 127.5,
128.0, 129.3, 129.7, 130.5, 130.7, 132.5, 138.0, 144.8,
163.3. LC–MS (ESI) m/z [M + H]+: 448.2. HRMS (EI) m/z
calcd for C20H18NO4SBr (M)+: 447.0140; found: 447.0147.
Ethyl 4-phenyl-5-tosyl-1H-pyrrole-3-carboxylate (3a)
Treatment of 1a (217 mg, 1.0 mmol) with 2 (390 mg,
2.0 mmol) by General procedure A gave 3a (188 mg, 51%)
as a pale yellow solid (EtOAc/hexane); mp 168–170 °C. IR
Ethyl 4-(2-bromophenyl)-5-tosyl-1H-pyrrole-3-carboxylate
(3e)
Treatment of 1e (296 mg, 1.0 mmol) with 2 (390 mg,
2.0 mmol) by General procedure A gave 3e (350 mg, 78%)
as an off-white solid (EtOAc/hexane); mp 179–181 °C. IR
(KBr, cm–1) n: 3450, 3219, 2982, 1690, 763. 1H NMR
(500 MHz, CDCl3) d: 1.01 (3H, t, J = 7.0 Hz), 2.38 (3H, s),
4.00–4.11 (2H, m), 7.11 (2H, d, J = 8.5 Hz), 7.21–7.24 (1H,
m), 7.28–7.32 (3H, m), 7.34–7.37 (1H, m), 7.45 (1H, d, J =
7.0 Hz), 7.61 (1H, d, J = 3.5 Hz), 9.92 (1H, brs). 13C NMR
(125 MHz, CDCl3) d: 14.0, 21.8, 60.2, 118.8, 125.3, 125.9,
126.7, 127.7, 128.7, 129.6, 129.7, 131.9, 132.8, 133.1,
137.4, 144.7, 163.3. LC–MS (ESI) m/z [M + H]+: 448.2.
HRMS (EI) m/z calcd for C20H18NO4SBr (M)+: 447.0140;
found: 447.0139.
1
(KBr, cm–1) n: 3451, 3234, 2986, 1684, 770, 698, 661. H
NMR (500 MHz, CDCl3) d: 1.07 (3H, t, J = 7.0 Hz), 2.34
(3H, s), 4.08 (2H, q, J = 7.0 Hz), 7.07 (2H, d, J = 8.0 Hz),
7.14 (2H, d, J = 7.5 Hz), 7.25 (2H, d, J = 8.0 Hz), 7.30 (2H,
t, J = 7.5 Hz), 7.34 (1H, d, J = 7.0 Hz), 7.58 (1H, d, J =
2.0 Hz), 10.07 (1H, brs). 13C NMR (125 MHz, CDCl3) d:
14.1, 21.7, 60.2, 117.9, 126.4, 127.4, 127.7, 128.0, 130.0,
130.7, 130.8, 131.5, 138.2, 144.4, 163.5. LC–MS (ESI) m/z
[M + H]+: 370.3. HRMS (EI) m/z calcd for C20H19NO4S
(M)+: 369.1035; found: 369.1033.
Ethyl 4-(4-methoxyphenyl)-5-tosyl-1H-pyrrole-3-
carboxylate (3b)
Ethyl 4-(4-fluorophenyl)-5-tosyl-1H-pyrrole-3-carboxylate
(3f)
Treatment of 1b (247 mg, 1.0 mmol) with 2 (390 mg,
2.0 mmol) by General procedure A gave 3b (168 mg, 42%)
as a pale yellow solid (EtOAc/hexane); mp 140–142 °C. IR
Treatment of 1f (235 mg, 1.0 mmol) with 2 (390 mg,
2.0 mmol) by General procedure A gave 3f (248 mg, 64%)
as a pale yellow solid (EtOAc/hexane); mp 183–185 °C. IR
1
(KBr, cm–1) n: 3451, 3236, 2987, 1674, 807, 768. H NMR
(500 MHz, CDCl3) d: 1.12 (3H, t, J = 7.0 Hz), 2.35 (3H, s),
3.86 (3H, s), 4.10 (2H, q, J = 7.0 Hz), 6.86 (2H, d, J =
8.5 Hz), 7.08–7.11 (4H, m), 7.28 (2H, d, J = 8.5 Hz), 7.56
(1H, d, J = 3 Hz), 10.13 (1H, brs). 13C NMR (125 MHz,
CDCl3) d: 14.1, 21.5, 55.3, 59.9, 112.8, 117.6, 123.4, 126.4,
127.2, 127.4, 129.4, 130.7, 131.8, 138.1, 144.2, 159.3, 163.4.
LC–MS (ESI) m/z [M + H]+: 400.4. HRMS (EI) m/z calcd
for C21H21NO5S (M)+: 399.1140; found: 399.1137.
1
(KBr, cm–1) n: 3451, 3220, 2986, 1686, 808, 781. H NMR
(500 MHz, CDCl3) d: 1.10 (3H, t, J = 7.0 Hz), 2.36 (3H, s),
4.09 (2H, q, J = 7.0 Hz), 6.98–7.02 (2H, m), 7.10–7.14 (4H,
m), 7.26–7.29 (2H, m), 7.59 (1H, s), 10.08 (1H, brs). 13C
NMR (125 MHz, CDCl3) d: 14.2, 21.8, 60.3, 114.5 (d, J =
21 Hz), 118.0, 126.5, 127.4, 127.9, 129.6, 129.7, 132.8 (d,
J = 8 Hz), 138.1, 144.7, 162.8 (d, J = 245 Hz), 163.4. LC–
MS (ESI) m/z [M + H]+: 388.3. HRMS (EI) m/z calcd for
C20H18NO4FS (M)+: 387.0941; found: 387.0938.
Ethyl 4-(benzo[d][1,3]dioxol-5-yl)-5-tosyl-1H-pyrrole-3-
carboxylate (3c)
Ethyl 4-(3, 4-dichlorophenyl)-5-tosyl-1H-pyrrole-3-
carboxylate (3g)
Treatment of 1c (261 mg, 1.0 mmol) with 2 (390 mg,
2.0 mmol) by General procedure A gave 3c (207 mg, 50%)
as a pale yellow solid (EtOAc/hexane); mp 173–175 °C. IR
Treatment of 1g (286 mg, 1.0 mmol) with 2 (390 mg,
2.0 mmol) by General procedure A gave 3g (272 mg, 62%)
as a pale yellow solid (EtOAc/hexane); mp 191–193 °C. IR
1
(KBr, cm–1) n: 3450, 3270, 2924, 1692, 810, 771. H NMR
(500 MHz, CDCl3) d: 1.14 (3H, t, J = 7.0 Hz), 2.37 (3H, s),
4.11 (2H, q, J = 7.0 Hz), 5.98 (2H, s), 6.57 (1H, d, J =
1.5 Hz), 6.62 (1H, dd, J1 = 1.5 Hz, J2 = 8.0 Hz), 6.76 (1H,
d, J = 8.0 Hz), 7.13 (2H, d, J = 8.5 Hz), 7.36 (2H, d, J =
8.5 Hz), 7.56 (d, 1H, J = 3.5 Hz), 10.11 (1H, brs). 13C
NMR (125 MHz, CDCl3) d: 14.3, 21.8, 60.2, 101.2, 107.5,
111.3, 117.9, 124.4, 124.9, 126.5, 127.5, 127.8, 129.6,
130.4, 138.2, 144.6, 146.9, 147.4, 163.4. LC–MS (ESI) m/z
[M + H]+: 414.3. HRMS (EI) m/z calcd for C21H19NO6S
(M)+: 413.0933; found: 413.0935.
1
(KBr, cm–1) n: 3451, 3237, 2924, 1686, 770, 672. H NMR
(500 MHz, CDCl3) d: 1.11 (3H, t, J = 7.0 Hz), 2.39 (3H, s),
4.10 (2H, q, J = 7.0 Hz), 7.03 (1H, s), 7.07 (1H, d, J =
8.0 Hz), 7.16 (2H, d, J = 8.0 Hz), 7.33 (2H, d, J = 8.0 Hz),
7.40 (1H, d, J = 8.0 Hz), 7.60 (1H, s). 13C NMR (125 MHz,
CDCl3) d: 14.2, 21.8, 60.4, 118.0, 126.3, 127.6, 128.5, 129.5,
129.8, 130.3, 131.5, 131.6, 132.3, 132.4, 137.8, 145.1, 163.1.
LC–MS (ESI) m/z [M + H]+: 438.2. HRMS (EI) m/z calcd
for C20H17NO4SCl2 (M)+: 437.0255; found: 437.0258.
Ethyl 4-(4-bromophenyl)-5-tosyl-1H-pyrrole-3-carboxylate
(3d)
Ethyl 4-(3-nitrophenyl)-5-tosyl-1H-pyrrole-3-carboxylate
(3h)
Treatment of 1d (296 mg, 1.0 mmol) with 2 (390 mg,
2.0 mmol) by General procedure A gave 3d (336 mg, 75%)
as a pale yellow solid (EtOAc/hexane); mp 185–187 °C. IR
Treatment of 1h (262 mg, 1.0 mmol) with 2 (390 mg,
2.0 mmol) by General procedure B gave 3h (356 mg, 86%)
as a pale yellow solid (EtOAc/hexane); mp 161–163 °C. IR
1
1
(KBr, cm–1) n: 3450, 3223, 2924, 1685, 818, 778. H NMR
(KBr, cm–1) n: 3451, 3250, 2984, 1689, 810, 737. H NMR
(500 MHz, CDCl3) d: 1.11 (3H, t, J = 7.0 Hz), 2.37 (3H, s),
4.09 (2H, q, J = 7.0 Hz), 7.02 (2H, d, J = 8.5 Hz), 7.12 (2H,
d, J = 8.5 Hz), 7.28 (2H, d, J = 8.5 Hz), 7.44 (2H, d, J =
(500 MHz, CDCl3) d: 1.07 (3H, t, J = 7.0 Hz), 2.36 (3H, s),
4.08 (2H, q, J = 7.0 Hz), 7.13 (2H, d, J = 8.0 Hz), 7.32 (2H,
d, J = 8 Hz), 7.54 (1H, t, J = 8.0 Hz), 7.62–7.64 (2H, m),
Published by NRC Research Press